GPCR Stock — Structure Therapeutics Inc.

Structure Therapeutics Inc. (GPCR)

Updated October 16, 2026.

GPCR is a Stock. Total return is 40.5% over the past 3.7 years, 51.5 points behind SPY at 92.0%.

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral small molecule drugs to treat chronic diseases, with a focus on obesity and related metabolic conditions through candidates targeting glucagon-like-peptide-1 receptor and related pathways, along with programs for idiopathic pulmonary fibrosis and other conditions. The company does not currently distribute dividends. This stock may appeal to investors seeking exposure to early-stage biotechnology development, though it carries the clinical and commercial risks typical of pre-revenue drug development companies.

GPCR performance versus SPY

Price and return data through 2026-10-16.

Total return is 40.5% over the past 3.7 years, 51.5 points behind SPY at 92.0%. Over the past year its total return — price change plus distributions reinvested — is -23.5%. Its deepest 1-year drawdown was 77.5%.

GPCR key facts

Asset type

Stock

Asset class

Equity

Inception date

02/02/2023

Distribution frequency

None

Last close

$21.08 (as of 2026-10-16)

Market cap

$1,503,211,786

Average volume

1160490.0

Beta

-1.368

Payout ratio

0.0%

EPS

$-3.03

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GPCR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 77.5%.

Who may consider GPCR — and who may not

It is a weaker fit for investors who need monthly cash flow (GPCR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on GPCR

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions